19:53 , Nov 2, 2018 |  BC Week In Review  |  Company News

Lilly is Dicerna's second RNAi partner within a week

Eli Lilly and Co. (NYSE:LLY) partnered with Dicerna Pharmaceuticals Inc. (NASDAQ:DRNA) on Oct. 29 to discover and develop RNAi therapies to treat cardiometabolic disorders, neurodegeneration and pain. The deal is the second RNAi collaboration Dicerna...
10:02 , Oct 29, 2018 |  BC Extra  |  Company News

Lilly is Dicerna's second RNAi partner in a week

Eli Lilly and Co. (NYSE:LLY) partnered with Dicerna Pharmaceuticals Inc. (NASDAQ:DRNA) to discover and develop RNAi therapies to treat cardiometabolic disorders, neurodegeneration and pain. The deal is the second RNAi collaboration Dicerna has made within...
17:13 , Oct 26, 2018 |  BC Week In Review  |  Company News

Alexion moves into RNAi with Dicerna deal

Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) entered into the RNAi field with a deal with Dicerna Pharmaceuticals Inc. (NASDAQ:DRNA) to discover and develop RNAi therapies for complement-mediated diseases. Alexion also reported higher-than-expected revenues and sales of Soliris...
23:07 , Oct 24, 2018 |  BC Extra  |  Company News

Alexion moves into RNAi with Dicerna deal

Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) entered into the RNAi field with a deal with Dicerna Pharmaceuticals Inc. (NASDAQ:DRNA) to discover and develop RNAi therapies for complement-mediated diseases. Alexion also reported higher-than-expected revenues and sales of Soliris...
23:30 , Oct 19, 2018 |  BioCentury  |  Finance

Earnings on deck

Earnings on deck...
01:19 , Oct 6, 2018 |  BioCentury  |  Finance

In sight of uncharted territory

Strong growth from small- and mid-caps coupled with a late run from large cap biotechs has pushed the sector within sight of its all-time high in 2015. Some buysiders now are seeing red flags of...
00:48 , Oct 6, 2018 |  BioCentury  |  Finance

Seeking validation

The final stretch of the year offers clinical catalysts and early launch data that could validate investments in hot immuno-oncology targets and large untapped markets. Late-stage readouts from Vertex Pharmaceuticals Inc. in cystic fibrosis and...
19:27 , Oct 5, 2018 |  BC Week In Review  |  Clinical News

Blueprint debuts selective ALK2 inhibitor for rare musculoskeletal disease

Blueprint Medicines Corp. (NASDAQ:BPMC) provided the first glimpse of its preclinical ALK2 inhibitor program, BLU-782, when it presented data at the American Society for Bone and Mineral Research (ASBMR) meeting in Montreal on Sept. 30....
15:30 , Sep 30, 2018 |  BC Extra  |  Preclinical News

Blueprint Medicines unveils preclinical data for rare bone disease program

Blueprint Medicines Corp. (NASDAQ:BPMC) provided the first glimpse of its preclinical ALK2 inhibitor program, BLU-782, when it presented data at the American Society for Bone and Mineral Research (ASBMR) meeting in Montreal on Sunday. Blueprint...
17:36 , Sep 28, 2018 |  BC Week In Review  |  Clinical News

Alexion eyes submissions for Soliris in rare CNS disease

Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) plans to submit regulatory applications in the U.S., EU and Japan for Soliris eculizumab to treat relapsing neuromyelitis optica spectrum disorder (NMOSD) after the drug met the primary endpoint in the...